BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 18, 2026
Breaking News: Tracking hantavirus across the globeBreaking News: WHO declares Ebola outbreak a public health emergency of international concernBreaking News: WHO declares Ebola outbreak a public health emergency of international concern
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Brain activity concept illustration
Biomarkers

Deleterious homozygous variants in NSUN6 linked to autosomal recessive neurodevelopmental delay

June 15, 2023
Researchers from the University of Lausanne and affiliated organizations recently presented data from studies that aimed to identify novel genes associated with neurodevelopmental disease (NDD).
Read More
Neurology/Psychiatric

Edgewise Therapeutics presents new myosin-2 inhibitors

June 14, 2023
Edgewise Therapeutics Inc. has divulged pyridazinone compounds acting as myosin-2 (MYH2) (ATPase activity) inhibitors reported to be useful for the treatment of Duchenne muscular dystrophy, amyotrophic lateral sclerosis, encephalitis, spinal cord injury, phenylketonuria, cerebral palsy, Alzheimer’s disease and Parkinson’s disease, among others.
Read More
Pediatric brain illustration
Neurology/Psychiatric

Efna2 and Cx43 in brain capillary endothelial cells affect age-dependent La Crosse virus-induced neurological disease

June 14, 2023
La Crosse virus (LACV) is one of the most common causes of arboviral encephalitis in children, which causes CNS damage owing to infection in children, but not adults. LACV pathology indicates significant breakdown of the blood-brain barrier, which is strengthened during developmental transition from child to adult.
Read More
Biomarkers

WBP4-related spliceosomopathy identified in patients with severe neurodevelopmental delay

June 14, 2023
The WW domain binding protein 4 (WBP4) is part of the early spliceosomal complex, and it has been previously shown to enhance splicing both in vitro and in vivo, as well as to regulate alternative splicing. At the ESHG meeting, researchers from Hebrew University of Jerusalem presented data from a study that aimed to delineate WBP4 in the context of human pathologies.
Read More
Genetic brain disorders, conceptual 3D illustration
Neurology/Psychiatric

Spinocerebellar ataxia variants show vast heterogeneity

June 14, 2023
By Mar de Miguel
The phenotypic variety of spinocerebellar ataxias (SCAs) not caused by CAG repeat expansion (polyglutamine SCA) is greater than expected. A collaboration directed by scientists of the Paris Brain Institute described seven variants of this disorder in 756 individuals, observing that age at onset and progression by gene and variant can occur from childhood to late adulthood with very different forms of the disease.
Read More
Neurology/Psychiatric

Hepaitech (Beijing) Biopharma patents new FXR and GPBAR1 agonists

June 13, 2023
Hepaitech (Beijing) Biopharma Technology Co. Ltd. has disclosed bile acids acting as farnesoid X receptor (FXR) and/or G-protein coupled bile...
Read More
Neurology/Psychiatric

Tetra Pharm Technologies reports in vitro findings with TPT-0301 for pain

June 13, 2023
Tetra Pharm Technologies Aps has announced promising results from preclinical testing of its pain-relieving drug, TPT-0301, which targets the endocannabinoid system.
Read More
Microscopic image of the blood-brain barrier in a mouse.
Neurology/Psychiatric

Novel FZD4-selective WNT surrogate improves stroke outcomes and BBB function in mice

June 13, 2023
Recent studies have demonstrated that WNT/β-catenin signaling is essential for the regulation of both blood-brain barrier (BBB) and blood...
Read More
Neurology/Psychiatric

Vigil Neuroscience divulges new TREM2 agonists

June 12, 2023
Vigil Neuroscience Inc. has synthesized heterocyclic compounds acting as triggering...
Read More
Multiple sclerosis
Neurology/Psychiatric

Pipeline Therapeutics cleared to advance LPA1 antagonist for multiple sclerosis

June 9, 2023
Pipeline Therapeutics Inc. has received FDA clearance to initiate a phase I trial of PIPE-791 in healthy volunteers, with dosing expected to begin in the second half of this year. PIPE-791 is advancing toward clinical development for remyelination and neuroinflammation, with a leading indication of multiple sclerosis (MS).
Read More
Previous 1 2 … 176 177 178 179 180 181 182 183 184 … 2803 2804 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • Doctor with brain illustration, businessman with dollar sign illustration

    Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

    BioWorld
    Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing